Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer (NCT04269200)
A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)
🩺 Plain-English Summary (8th-Grade Level)
A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.
Who can join: Review the eligibility criteria below.
Location: Research Site — Tucson, Arizona
Age range: 18 Years to 150 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (201 Sites)
Showing the first 25 of 201 sites.
- Research Site — Tucson, Arizona
- Research Site — Concord, California
- Research Site — La Jolla, California
- Research Site — San Francisco, California
- Research Site — Santa Barbara, California
- Research Site — Aurora, Colorado
- Research Site — Fort Lauderdale, Florida
- Research Site — Tampa, Florida
- Research Site — Savannah, Georgia
- Research Site — Honolulu, Hawaii
- Research Site — Arlington Heights, Illinois
- Research Site — Chicago, Illinois
- Research Site — Indianapolis, Indiana
- Research Site — Louisville, Kentucky
- Research Site — Baton Rouge, Louisiana
- Research Site — Boston, Massachusetts
- Research Site — Saint Paul, Minnesota
- Research Site — Jackson, Mississippi
- Research Site — Lebanon, New Hampshire
- Research Site — Camden, New Jersey
- Research Site — Paramus, New Jersey
- Research Site — New York, New York
- Research Site — New York, New York
- Research Site — Pinehurst, North Carolina
- Research Site — Cleveland, Ohio
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Endometrial Neoplasms
- A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor — Little Rock, Arkansas
- Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) — Phoenix, Arizona
- Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) — Birmingham, Alabama
Explore by condition: All Endometrial Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.